New FDA Approvals

Ojjaara for Anemia in Myelofibrosis, Resmetirom for NASH, COVID-19 Vaccine Update, Phenylephrine, Patisiran in ATTR-CM


Listen Later

In this week's New FDA Approval's podcast episode, Dr. Emma Hitt Nichols discusses the latest FDA approvals from September 11, 2023 – September 15, 2023.  Please check back every Monday morning so that you can stay up to date. 

See more details summaries and links to prescribing information at nascentmc.com/podcast

Here are the highlights:

• Ojjaara for Anemia in Myelofibrosis: FDA approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis in adults with anemia. This drug is unique as it serves both newly diagnosed and previously treated patients, addressing anemia, constitutional symptoms, and splenomegaly. Approval was based on the MOMENTUM phase 3 trial results.

• Resmetirom for NASH: FDA granted priority review for resmetirom, aiming to treat non-alcoholic steatohepatitis (NASH). Madrigal, its manufacturer, seeks approval via the FDA’s accelerated pathway. Resmetirom is evaluated in four phase 3 trials, including MAESTRO-NASH. The decision is set for March 14, 2024.

• Updated COVID-19 Vaccines: FDA approved updated vaccines for the coming season targeting the omicron descendant XBB.1.5. While older vaccines targeted earlier strains, these new shots might provide protection against prevalent related strains. Pfizer, Moderna, and Novavax are manufacturing the vaccines.

• Phenylephrine Lack of Efficacy: An FDA panel unanimously found phenylephrine, present in OTC decongestants like Sudafed and Dayquil, ineffective for its intended use. If the FDA agrees, over 250 products containing phenylephrine might be withdrawn from the market. This decision does not affect nasal preparations.

• Patisiran for ATTR-CM: The FDA’s advisory committee voted that the benefits of patisiran surpass its risks for treating cardiomyopathy induced by transthyretin amyloidosis (ATTR-CM). Although the drug showed small effects compared to placebo in the Phase III APOLLO-B study, it met primary and secondary endpoints. The FDA's decision will be made on or before Oct. 8, 2023.

Intro and outro music

Garden Of Love by Pk jazz Collective

 

 

...more
View all episodesView all episodes
Download on the App Store

New FDA ApprovalsBy Emma Hitt Nichols, PhD

  • 5
  • 5
  • 5
  • 5
  • 5

5

4 ratings


More shows like New FDA Approvals

View all
NEI Podcast by Neuroscience Education Institute

NEI Podcast

129 Listeners

NEJM This Week by NEJM Group

NEJM This Week

325 Listeners

JAMA Clinical Reviews by JAMA Network

JAMA Clinical Reviews

493 Listeners

STEM-Talk by Dawn Kernagis and Ken Ford

STEM-Talk

652 Listeners

The Curbsiders Internal Medicine Podcast by The Curbsiders Internal Medicine Podcast

The Curbsiders Internal Medicine Podcast

3,332 Listeners

JAMA Medical News by JAMA Network

JAMA Medical News

90 Listeners

The Long Run with Luke Timmerman by Timmerman Report

The Long Run with Luke Timmerman

122 Listeners

AHLA's Speaking of Health Law by American Health Law Association

AHLA's Speaking of Health Law

28 Listeners

Real Life Pharmacology - Pharmacology Education for Health Care Professionals by Eric Christianson, PharmD; Pharmacology Expert and Clinical Pharmacist

Real Life Pharmacology - Pharmacology Education for Health Care Professionals

716 Listeners

The Readout Loud by STAT

The Readout Loud

318 Listeners

The Carlat Psychiatry Podcast by Pocket Psychiatry: A Carlat Podcast

The Carlat Psychiatry Podcast

559 Listeners

Business Of Biotech by Ben Comer

Business Of Biotech

88 Listeners

CEimpact Podcast by CEimpact

CEimpact Podcast

17 Listeners

Truth, Lies & Alzheimer's by Lisa Skinner

Truth, Lies & Alzheimer's

15 Listeners

Conversations in Drug Development by Boyds

Conversations in Drug Development

3 Listeners